Market Opportunity

We believe that PPL-138 has the potential to reach annual sales of $2B by 2028, while the prescription opioid market is projected to reach $35B by 2025. The company anticipates that PPL-103 has similar potential in terms of market penetration, as it will focus specifically on treatment for addiction and also chronic and acute pain. According to P&S Intelligence, the chronic pain treatment market is growing due to the rising prevalence of chronic conditions and a surging geriatric population, and is expected to reach $105.9B by 2024.


The strategic objective of the company is to partner with appropriate market leader(s) that have the resources to maximize the market potential of the Phoenix compounds. Several leading pharma companies that have a strategic focus on pain have indicated interest in partnering by the end of Phase 1. We plan to advance PPL-138 into Phase 1 clinical trials in 2022-2023, and position it for optimal deal terms, ideally by 2024. Phoenix will then use a portion of license fee proceeds to advance PPL-103 for addiction therapy and for pain into Phase 1 clinical trials and continuing to continue to Proof of Concept. Phoenix plans to register the Company as publicly-traded in the next few years so that investors may choose to realize the future values of cash flows.


Phoenix has received strong validation of its science from the NIH and the USAMRMC, which awarded the company grants of about $5 million to fund the advancement of its compounds into human clinical trials. Grant funds have been supplemented with approximately $3 million of private equity investment including a $2 million online public offering of private securities in 2019 and in 2021 that were oversubscribed under SEC Rule CF. The company is currently applying for additional grants as well as raising funds through private equity investment to fund the further advancement of its compounds.